Home » Stocks » VECT » Company

VectivBio Holding AG (VECT)

Stock Price: $24.23 USD 7.23 (42.53%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
VectivBio Holding AG
Founded 2019
IPO Date Apr 9, 2021

Stock Information

Ticker Symbol VECT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $17.00
CIK Code 1836379

Company Description

VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need.

Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets.

Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS.

Apraglutide is currently being evaluated in a global Phase 3 clinical trial for the treatment of patients with SBS intestinal failure, or SBS-IF. We also plan to evaluate apraglutide’s therapeutic potential in additional rare GI conditions, such as graft versus host disease, that could benefit from GLP-2 activation.

Key Executives

Dr. Luca Santarelli Chief Executive Officer and Director
Dr. Claudia D’Augusta Chief Financial Officer
Dr. Christian Meyer Chief Development Officer
Kevin Harris Chief Commercial Officer
Dr. Alain Bernard Chief Technology Officer
Dr. Sarah Holland Chief Business Officer
Dr. Thomas Woiwode Chairman of the Board
Timothy Anderson Director